Who
Leslie D. Funtleyder
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Applied Therapeutics; Director, Reviva Pharmaceuticals Holdings.
In numbers
- Trades disclosed
- 101
- Buys
- 0
- Sells
- 22
- Bought
- $0
- Sold
- $5.3M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 16 May 2019
- Last trade
- 3 Feb 2026
- Last filed
- 3 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Feb 2026filed 3 Feb 2026 | Applied TherapeuticsBiotechnology | SEC FORM 4 Code D | —2,375,000 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied TherapeuticsBiotechnology | SEC FORM 4 Code U | —152,959 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied Therapeuticsoption or derivative | SEC FORM 4 Code D | —20,460 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied Therapeuticsoption or derivative | SEC FORM 4 Code D | —10,230 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied Therapeuticsoption or derivative | SEC FORM 4 Code D | —16,500 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied Therapeuticsoption or derivative | SEC FORM 4 Code D | —16,500 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied Therapeuticsoption or derivative | SEC FORM 4 Code D | —150,000 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied Therapeuticsoption or derivative | SEC FORM 4 Code D | —40,502 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —20,460 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,230 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —16,500 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —16,500 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —150,000 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied Therapeutics | SEC FORM 4 Code D | —2,375,000 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied Therapeutics | SEC FORM 4 Code U | —152,959 | filing |
| 3 Feb 2026filed 3 Feb 2026 | Applied Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —40,502 | filing |
| 1 Jan 2026filed 2 Jan 2026 | Applied TherapeuticsBiotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 1 Jan 2026filed 2 Jan 2026 | Applied Therapeutics | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 19 Dec 2025filed 3 Feb 2026 | Applied TherapeuticsBiotechnology | SEC FORM 4 Code A | —1,187,500 at $0.00 | filing |
| 19 Dec 2025filed 3 Feb 2026 | Applied Therapeutics | SEC FORM 4 Code A | —1,187,500 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.